Interim analysis: Open-label extension study of leniolisib for patients with APDS-Reference-Cited by-同舟云学术

Interim analysis: Open-label extension study of leniolisib for patients with APDS

Published:2024-01 Issue:1 Volume:153 Page:265-274.e9
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Rao V. Koneti^ORCID,Kulm Elaine,Šedivá Anna,Plebani Alessandro,Schuetz Catharina,Shcherbina Anna,Dalm Virgil A.,Trizzino Antonino,Zharankova Yulia,Webster Sharon,Orpia Alanvin,Körholz Julia,Lougaris Vassilios,Rodina Yulia,Radford Kath,Bradt Jason,Relan Anurag,Holland Steven M.,Lenardo Michael J.,Uzel Gulbu

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference44 articles.

1. The treatment of activated PI3Kdelta syndrome;Coulter;Front Immunol,2018

2. PI3K pathway defects leading to immunodeficiency and immune dysregulation;Nunes-Santos;J Allergy Clin Immunol,2019

3. Hyperactivated PI3Kdelta promotes self and commensal reactivity at the expense of optimal humoral immunity;Preite;Nat Immunol,2018